Lutris Pharma’s LUT014 Gel Shows Promise in Treating Skin Rash from Cancer Therapies at ESMO 2025 Lutris Pharma presents encouraging results from a Phase 2 study of LUT014 Gel, demonstrating its effectiveness against acneiform rash from anti-EGFR therapies, enhancing patients' treatment adherence.

Lutris Pharma’s LUT014 Gel Shows Promise in Treating Skin Rash from Cancer Therapies at ESMO 2025 #Israel #Tel_Aviv #Lutris_Pharma #LUT014 #EGFR_Therapies

Lutris Pharma to Share Results from Phase 2 Trial of LUT014 Gel for Treating EGFRI-Induced Acneiform Rash at ESMO 2025 Lutris Pharma is set to present data from its Phase 2 trial of LUT014 gel, aimed at treating acneiform rash induced by EGFR inhibitors, at ESMO 2025.

Lutris Pharma to Share Results from Phase 2 Trial of LUT014 Gel for Treating EGFRI-Induced Acneiform Rash at ESMO 2025 #Israel #Tel_Aviv #Lutris_Pharma #LUT014 #ESMO_Congress

Lutris Pharma Welcomes Sumant Ramachandra as New CEO to Revolutionize Cancer Therapy Lutris Pharma has appointed Dr. Sumant Ramachandra as its new CEO, promising to enhance cancer treatments and patient quality of life.

Lutris Pharma Welcomes Sumant Ramachandra as New CEO to Revolutionize Cancer Therapy #USA #Tel_Aviv #Lutris_Pharma #LUT014 #Sumant_Ramachandra

Lutris Pharma's LUT014 Gel Shows Promise in Treating Acne Rash Linked to Cancer Therapies At the AACR Annual Meeting 2025, Lutris Pharma unveiled promising data for its LUT014 gel, demonstrating efficacy in treating acneiform rash in cancer patients, enhancing care outcomes.

Lutris Pharma's LUT014 Gel Shows Promise in Treating Acne Rash Linked to Cancer Therapies #USA #Tel_Aviv #Lutris_Pharma #LUT014 #BRAF_Inhibitor

Lutris Pharma Reveals Promising Data at AACR 2025 Conference on Targeted Therapy for Cancer-Related Skin Issues Lutris Pharma is set to present findings from a Phase 2 study of LUT014, a topical treatment aimed at combating skin side effects common with anti-cancer therapies, at AACR 2025.

Lutris Pharma Reveals Promising Data at AACR 2025 Conference on Targeted Therapy for Cancer-Related Skin Issues #USA #Chicago #Lutris_Pharma #LUT014 #EGFR_inhibitors

Lutris Pharma Receives $30 Million Financing for Cancer Therapy Advancements Lutris Pharma announces a $30 million funding round aimed at enhancing the development of an innovative treatment for skin toxicity in cancer therapy, promising better patient outcomes.

Lutris Pharma Receives $30 Million Financing for Cancer Therapy Advancements #Lutris_Pharma #LUT014 #EGFR_inhibitors